Aglatimagene besadenovec is under clinical development by Candel Therapeutics and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to GlobalData, Phase II drugs for Pancreatic Ductal Adenocarcinoma does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Aglatimagene besadenovec LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Aglatimagene besadenovec overview
Aglatimagene besadenovec is under development for the treatment of non-small cell lung cancer, high grade glioma, glioblastoma multiforme, recurrent glioblastoma multiforme, anaplastic astrocytoma, recurrent, advanced non-metastatic pancreatic ductal adenocarcinoma and prostate cancer. The therapeutic candidate consists of (AdV-tk) adenoviral replication-defective engineered gene construct encoding the thymidine kinase gene derived from herpes simplex virus (HSV). It is administered through parenteral and intra-tumoral route and is being developed based on enLIGHTEN Discovery Platform.
The therapeutic candidate was also under development for the treatment of malignant glioma and ependymomas.
Candel Therapeutics overview
Candel Therapeutics is a biopharmaceutical company. It manufactures, develops and tests cancer immunotherapy drugs and gene-based biologics. Candel Therapeutics offers CAN-2409 and CAN-3110, for the treatment of a broad range of solid tumor indications. It is focused on developing oncolytic viral immunotherapies for the treatment of cancer patients. The company’s oncolytic viral immunotherapy platforms use genetically engineered viruses to induce immunogenic death through viral-mediated cytotoxicity in cancer cells. Its products, CAN-3110 and CAN-2409 are used in the treatment of prostate cancer, brain cancer, pancreatic cancer, lung cancer, malignant pleural effusion and mesothelioma. Candel Therapeutics is headquartered in Needham, Massachusetts, the US.
For a complete picture of Aglatimagene besadenovec’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
